Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2014

01-11-2014 | Review

SOCS6 is a selective suppressor of receptor tyrosine kinase signaling

Authors: Nuzhat N. Kabir, Jianmin Sun, Lars Rönnstrand, Julhash U. Kazi

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

The suppressors of cytokine signaling (SOCS) are well-known negative regulators of cytokine receptor signaling. SOCS6 is one of eight members of the SOCS family of proteins. Similar to other SOCS proteins, SOCS6 consists of an uncharacterized extended N-terminal region followed by an SH2 domain and a SOCS box. Unlike other SOCS proteins, SOCS6 is mainly involved in negative regulation of receptor tyrosine kinase signaling. SOCS6 is widely expressed in many tissues and is found to be downregulated in many cancers including colorectal cancer, gastric cancer, lung cancer, ovarian cancer, stomach cancer, thyroid cancer, hepatocellular carcinoma, and pancreatic cancer. SOCS6 is involved in negative regulation of receptor signaling by increasing degradation mediated by ubiquitination of receptors or substrate proteins and induces apoptosis by targeting mitochondrial proteins. Therefore, SOCS6 turns out as an important regulator of survival signaling and its activity is required for controlling receptor tyrosine kinase signaling.
Literature
1.
Kazi JU, Kabir NN, Flores-Morales A, Rönnstrand L. SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci. 2014;71:3297–310.
2.
Kazi JU, Rönnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol. 2013;7:693–703.PubMedCrossRef
3.
Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem. 2012;287:36509–17.PubMedCentralPubMedCrossRef
4.
Zadjali F, Pike AC, Vesterlund M, Sun J, Wu C, Li SS, et al. Structural basis for c-Kit inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem. 2011;286:480–90.
5.
Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P. Suppressor of cytokine signaling 6 associates with Kit and regulates Kit receptor signaling. J Biol Chem. 2004;279:12249–59.
6.
Matuoka K, Miki H, Takahashi K, Takenawa T. A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun. 1997;239:488–92.PubMedCrossRef
7.
Martens N, Wery M, Wang P, Braet F, Gertler A, Hooghe R, et al. The suppressor of cytokine signaling (SOCS)-7 interacts with the actin cytoskeleton through vinexin. Exp Cell Res. 2004;298:239–48.PubMedCrossRef
8.
De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 1999;18:904–15.PubMedCentralPubMedCrossRef
9.
Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem. 2002;277:42394–8.PubMedCrossRef
10.
Gui Y, Yeganeh M, Ramanathan S, Leblanc C, Pomerleau V, Ferbeyre G, et al. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol. 2011;55:1300–8.PubMedCrossRef
11.
Hafizi S, Alindri F, Karlsson R, Dahlbäck B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun. 2002;299:793–800.PubMedCrossRef
12.
Dey BR, Spence SL, Nissley P, Furlanetto RW. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem. 1998;273:24095–101.PubMedCrossRef
13.
Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem. 2002;277:30716–23.PubMedCrossRef
14.
Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci. 2006;119:380–7.PubMedCrossRef
15.
Sasi W, Jiang WG, Sharma A, Mokbel K. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 2010;10:178.PubMedCentralPubMedCrossRef
16.
Kile BT, Alexander WS. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci. 2001;58:1627–35.PubMedCrossRef
17.
Li L, Gronning LM, Anderson PO, Li S, Edvardsen K, Johnston J, et al. Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem. 2004;279:34107–14.PubMedCrossRef
18.
Lai RH, Hsiao YW, Wang MJ, Lin HY, Wu CW, Chi CW, et al. SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett. 2010;288:75–85.PubMedCrossRef
19.
Lin HY, Lai RH, Lin ST, Lin RC, Wang MJ, Lin CC, et al. Suppressor of cytokine signaling 6 (SOCS6) promotes mitochondrial fission via regulating DRP1 translocation. Cell Death Differ. 2013;20:139–53.PubMedCentralPubMedCrossRef
20.
Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997;239:439–46.PubMedCrossRef
21.
Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem. 1999;274:35553–61.PubMedCrossRef
22.
Helman D, Sandowski Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S, et al. Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling. FEBS Lett. 1998;441:287–91.PubMedCrossRef
23.
Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375–85.PubMedCentralPubMedCrossRef
24.
Lai RH, Wang MJ, Yang SH, Chen JY. Genomic organization and functional characterization of the promoter for the human suppressor of cytokine signaling 6 gene. Gene. 2009;448:64–73.PubMedCrossRef
25.
Dowton SB, Hing AV, Sheen-Kaniecki V, Watson MS. Chromosome 18q22.2 → qter deletion and a congenital anomaly syndrome with multiple vertebral segmentation defects. J Med Genet. 1997;34:414–7.PubMedCentralPubMedCrossRef
26.
Yoon S, Yi YS, Kim SS, Kim JH, Park WS, Nam SW. SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2012;33:215–21.CrossRef
27.
Hwang MN, Ha TH, Park J, Shim J, Lee H, Kim YN, et al. Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via PKC delta activation. Biochem Biophys Res Commun. 2007;354:184–9.
28.
Kazi JU, Kabir NN, Rönnstrand L. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol. 2013;30:757.PubMedCrossRef
29.
Kazi JU. The mechanism of protein kinase C regulation. Front Biol. 2011;6:328–36.
30.
Kazi JU, Kim CR, Soh JW. Subcellular localization of diacylglycerol-responsive protein kinase C isoforms in HeLa cells. Bull Kor Chem Soc. 2009;30:1981–4.
31.
Kazi JU, Soh JW. Role of regulatory domain mutants of PKC isoforms in c-fos induction. Bull Kor Chem Soc. 2008;29:252–4.CrossRef
32.
Kazi JU, Soh JW. Induction of the nuclear proto-oncogene c-fos by the phorbol ester TPA and v-H-Ras. Mol Cells. 2008;26:462–7.PubMed
33.
Piao L, Park J, Li Y, Shin S, Shin S, Kong G, et al. SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells. Int J Mol Med. 2014;33:1364–70.
34.
Storojeva I, Boulay JL, Ballabeni P, Buess M, Terracciano L, Laffer U, et al. Prognostic and predictive relevance of DNAM-1, SOCS6 and CADH-7 genes on chromosome 18q in colorectal cancer. Oncology. 2005;68:246–55.PubMedCrossRef
35.
Sriram KB, Larsen JE, Savarimuthu Francis SM, Wright CM, Clarke BE, Duhig EE, et al. Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One. 2012;7:e30398.PubMedCentralPubMedCrossRef
36.
Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, et al. Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem. 2013;378:99–106.PubMedCrossRef
37.
Wu K, Hu G, He X, Zhou P, Li J, He B, et al. MicroRNA-424-5p suppresses the expression of SOCS6 in pancreatic cancer. Pathol Oncol Res POR. 2013;19:739–48.CrossRef
38.
Tanaka T, Arai M, Jiang X, Sugaya S, Kanda T, Fujii K, et al. Downregulation of microRNA-431 by human interferon-beta inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. Int J Oncol. 2014;44:1685–90.
39.
Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y, et al. Mir-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett. 2014;588:2055–62.
40.
Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem. 2001;276:25889–93.PubMedCrossRef
41.
42.
Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002;22:4567–78.PubMedCentralPubMedCrossRef
43.
Banks AS, Li J, McKeag L, Hribal ML, Kashiwada M, Accili D, et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest. 2005;115:2462–71.PubMedCentralPubMedCrossRef
44.
Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, et al. Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem. 2003;278:48453–66.PubMedCrossRef
45.
Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol. 2002;22:965–77.PubMedCentralPubMedCrossRef
46.
Kabir NN, Kazi JU. Grb10 is a dual regulator of receptor tyrosine kinase signaling. Mol Biol Rep. 2014;41:1985–92.PubMedCrossRef
47.
Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, et al. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-Kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997;272:10248–53.
48.
Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem. 2001;276:4872–8.
49.
Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619–49.
50.
Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L. Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. J Cell Sci. 2014;127:653–62.
51.
Sun J, Mohlin S, Lundby A, Kazi JU, Hellman U, Påhlman S, et al. The PI3-kinase isoform p110delta is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner. Oncogene. 2013. doi:10.​1038/​onc.​2013.​479.
52.
Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal. 2013;25:1852–60.PubMedCrossRef
53.
Kazi JU, Kabir NN, Soh JW. Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene. 2008;410:147–53.PubMedCrossRef
54.
Kabir NN, Rönnstrand L, Kazi JU. Flt3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Med Oncol. 2013;30:462.
55.
Ben-Yair L, Slaaby R, Herman A, Cohen Y, Biener E, Moran N, et al. Preparation and expression of biologically active prolactin and growth hormone receptors and suppressor of cytokine signaling proteins 1, 2, 3, and 6 tagged with cyan and yellow fluorescent proteins. Protein Expr Purif. 2002;25:456–64.PubMedCrossRef
56.
Hwang MN, Min CH, Kim HS, Lee H, Yoon KA, Park SY, et al. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun. 2007;360:333–8.PubMedCrossRef
57.
Bayle J, Lopez S, Iwai K, Dubreuil P, De Sepulveda P. The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett. 2006;580:2609–14.PubMedCrossRef
Metadata
Title
SOCS6 is a selective suppressor of receptor tyrosine kinase signaling
Authors
Nuzhat N. Kabir
Jianmin Sun
Lars Rönnstrand
Julhash U. Kazi
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2542-4

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue

Research Article

Bufalin induces cell cycle arrest and apoptosis in gallbladder carcinoma cells

Research Article

Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer

Research Article

EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study

Research Article

Plasma interleukin-11 (IL-11) levels have diagnostic and prognostic roles in patients with pancreatic cancer

Review

Role of microRNA-93 in regulation of angiogenesis

Research Article

RETRACTED ARTICLE: Betulin inhibits lung carcinoma proliferation through activation of AMPK signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits